Clinical Trials
16 trialsNCT07621601 2026-06-02
A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Hansoh BioMedical R&D Company
Phase 3 Not yet recruiting
NCT04210115 2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04550260 2026-05-13
KUNLUN
AstraZeneca
Phase 3 Active not recruiting
NCT05357846 2026-04-30
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT07463573 2026-04-24
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07177794 2026-04-21
EC-CRT-008
Sun Yat-sen University
Phase 3 Recruiting
NCT04543617 2026-04-17
SKYSCRAPER-07
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06304974 2026-04-17
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT03957590 2026-04-13
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 3 Completed
NCT06952621 2026-01-30
TD-NEOE3V3
Tang-Du Hospital
Phase 3 Not yet recruiting
NCT06644781 2026-01-12
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Daiichi Sankyo
Phase 3 Recruiting
NCT04949256 2025-12-15
MK-7902-014
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT07246330 2025-11-24
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT03783442 2025-07-29
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT07016737 2025-06-12
ESO-Nanjing12
Jiangsu Cancer Institute & Hospital
Phase 3 Enrolling by invitation
NCT05078047 2025-06-05
MOIO
UNICANCER
Phase 3 Recruiting